Affimed - Model AFM13 -Innate Cell Engager Molecule
Lighting the way with clinical results: we are creating success with monotherapies and combination therapies. AFM13, a first-in-class ICE (innate cell engager) molecule targeting patients with CD30-positive lymphomas,4 showed antitumor responses in a Phase 1/2 trial as a monotherapy in 15 patients with T-cell lymphomas and cutaneous involvement (44% ORR).5 When used in combination with allogeneic NK cells (pre-complexing of AFM13 + cbNK), early clinical data in heavily pre-treated patients with Hodgkin lymphoma show a reduction in tumor burden as well as favorable safety.
When used in combination with an anti–PD-1 antibody in Hodgkin lymphoma, AFM13 demonstrated promising signs of efficacy, including an ORR of 88% at the highest treatment dose, as well as a CR of 46% (per independent assessment).7 Both ORR and CR rates were higher in combination with AFM13 than with the anti–PD-1 antibody alone.
Broad applicability expands horizons for those we can help
Preclinical data of AFM24 indicate promising efficacy across a wide variety of solid tumor types, including, but not limited to lung, colon, renal, and gastric cancers.8 Clinical data are currently being generated, and if successful, AFM24 could address a significant patient population underserved by current therapies. Emerging clinical data of AFM13 demonstrate impressive efficacy across a number of lymphoma types, including T-cell lymphoma and Hodgkin lymphoma.5,7
We are awaiting highly anticipated results in several EGFR-expressing tumors (eg, lung, RCC, CRC), T-cell lymphoma, Hodgkin lymphoma, and additional CD30-positive lymphomas.